-
Fallopian Tube Cancer Pipeline Outlook Report 2025: Key 70+ Companies And Breakthrough Therapies Shaping The Future Landscape
13 Aug 2025 00:34 GMT
… OncXerna Therapeutics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui … the treatment of ovarian cancer, Fallopian tube cancer and several other … Introduction
Executive Summary
Fallopian Tube Cancer: Overview
Pipeline Therapeutics
Therapeutic …
-
Alkermes plc (ALKS): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential
03 May 2025 22:04 GMT
… points (see more details here). Alkermes plc (ALKS): Among Billionaire Jim Simons’ RenTech … Hedge Fund Holders: 36 Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company … health, neurological conditions, and cancer. Its key products include treatments …
-
Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript
03 May 2025 12:50 GMT
Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript May 1, 2025
Alkermes plc misses on … : Good morning. Welcome to the Alkermes Plc conference call to discuss our … , following a courageous battle with cancer. Known to many of you …
-
Why Alkermes Tumbled On Its Positive Narcolepsy Study
21 Jul 2025 23:56 GMT
Alkermes (ALKS) stock skidded Monday — while … The Multibillion Dollar Cancer Detection Market
Alkermes said its orexin-focused … in earlier-stage testing of Alkermes' alixorexton. Evercore … potential for visual disturbances with Alkermes' drug could …
-
High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight
08 May 2025 17:00 GMT
… (Rina-S), Nemvaleukin alfa (ALKS 4230), Olvimulogene nanivacirepvec (Olvi- … cancer market share @ Ovarian Cancer Market Report Ovarian Cancer Overview Ovarian cancer … oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, …
-
After Alkermes' makeover, CEO Richard Pops touts its pipeline program and rare biotech model
13 Jan 2025 17:04 GMT
… business underneath it,” Richard Pops, Alkermes’ chairman and CEO, said … in 2023, when Alkermes spun off its cancer business into an … 39;s lead pipeline asset, ALKS 2680, is in a phase … Pops said.
Until ALKS 2680 hits the market, Alkermes will generate much …
-
Alkermes plc (NASDAQ:ALKS) Shares Purchased by Arizona State Retirement System
05 Feb 2024 11:55 GMT
… its holdings in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 2 … development for neurological disorders and cancer.
Featured Articles
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …
-
Alkermes plc (NASDAQ:ALKS) Stock Holdings Boosted by Los Angeles Capital Management LLC
03 Feb 2024 10:35 GMT
… its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 120 … development for neurological disorders and cancer.
See Also
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …
-
Raymond James & Associates Buys 6,510 Shares of Alkermes plc (NASDAQ:ALKS)
01 Feb 2024 09:36 GMT
… its holdings in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 32 … development for neurological disorders and cancer.
See Also
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …
-
Alkermes plc Expected to Post FY2024 Earnings of $2.47 Per Share (NASDAQ:ALKS)
01 Feb 2024 09:42 GMT
Alkermes plc (NASDAQ:ALKS – Free Report) – Equities research analysts … by institutional investors.
Alkermes Company Profile
(Get Free Report)
Alkermes plc, a biopharmaceutical … disorders and cancer.
Read More
Receive News & Ratings for Alkermes Daily …
About
© 1995-2025